Antibodies to HLA class I antigens in seronegative individuals at risk for HIV exposure

A. Beretta(San Raffaele University of Rome), Mario Clerici(University of Milan), Adriano Lazzarin(Vita-Salute San Raffaele University), Antonio G. Siccardi(San Raffaele University of Rome), Lucia Lopalco(Vita-Salute San Raffaele University), Claudio DeSantis, G M Shearer(National Institutes of Health), Stanley H. Weiss, Giovanna Rappocciolo(Vita-Salute San Raffaele University)
Unknown
September 21, 1994
Cited by 0

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Guidelines for the use of flow cytometry and cell sorting in immunological studies <sup>*</sup>
|European Journal of Immunology|2017|554
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391